Literature DB >> 22632132

Licensing of killer dendritic cells in mouse and humans: functional similarities between IKDC and human blood γδ T-lymphocytes.

John Anderson1, Kenth Gustafsson, Nourredine Himoudi.   

Abstract

Dendritic cells are characterized by the ability to induce primary antigen-specific immune responses in both major histocompatibility complex (MHC) Class I-restricted CD8 cells and MHC Class II-restricted CD4 cells. This professional antigen presentation function is associated with the up-regulation of co-stimulatory molecules and Class II MHC. While it has been recognized that several types of innate lymphocytes in mouse and humans can express co-stimulatory molecules and present antigen, the property of antigen presentation to elicit responses in naïve cells has been considered the exclusive domain of the dendritic cell. This concept has been challenged through the description of innate lymphocytes, capable of killing using NK receptors, but also up-regulating co-stimulatory molecules and driving the antigen-specific proliferation of naïve lymphocytes to the same extent as dendritic cells. Interferon (IFN)-γ secreting killer dendritic cells (IKDC) have been described in mice and share immunophenotypic properties of both dendritic cells and natural killer cells. Human blood γδ T-lymphocytes have innate tumor cell killing properties by both antibody-dependent and natural killer receptor-dependent mechanisms. This article reviews data from the authors' own laboratory showing a particular feature in common between the mouse IKDC and human blood γδ T-lymphocytes; namely their requirement for interaction with a target cell for specific licensing for professional antigen presentation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22632132     DOI: 10.3109/1547691X.2012.685528

Source DB:  PubMed          Journal:  J Immunotoxicol        ISSN: 1547-691X            Impact factor:   3.000


  4 in total

1.  Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study.

Authors:  Eytan Ben-Ami; Constance M Barysauskas; Sarah Solomon; Kadija Tahlil; Rita Malley; Melissa Hohos; Kathleen Polson; Margaret Loucks; Mariano Severgnini; Tara Patel; Amy Cunningham; Scott J Rodig; F Stephen Hodi; Jeffrey A Morgan; Priscilla Merriam; Andrew J Wagner; Geoffrey I Shapiro; Suzanne George
Journal:  Cancer       Date:  2017-04-25       Impact factor: 6.860

2.  Activation and measurement of NLRP3 inflammasome activity using IL-1β in human monocyte-derived dendritic cells.

Authors:  Melissa V Fernandez; Elizabeth A Miller; Nina Bhardwaj
Journal:  J Vis Exp       Date:  2014-05-22       Impact factor: 1.355

Review 3.  Clinical applications of gamma delta T cells with multivalent immunity.

Authors:  Drew C Deniger; Judy S Moyes; Laurence J N Cooper
Journal:  Front Immunol       Date:  2014-12-11       Impact factor: 7.561

4.  Tumor-activated TCRγδ⁺ T cells from gastric cancer patients induce the antitumor immune response of TCRαβ⁺ T cells via their antigen-presenting cell-like effects.

Authors:  Chaoming Mao; Xiao Mou; Yuepeng Zhou; Guoyue Yuan; Chengcheng Xu; Hongli Liu; Tingting Zheng; Jia Tong; Shengjun Wang; Deyu Chen
Journal:  J Immunol Res       Date:  2014-03-31       Impact factor: 4.818

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.